Organization (Academic)
University of Lorraine
ClinicalTrials.gov lists University of Lorraine as lead sponsor of 12 trials. It has 2 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Université de Lorraine, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers University of Lorraine: 12 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (36)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Anxiety Disorders | 4 |
| Breast Neoplasms | 3 |
| Obesity | 3 |
| Asthma | 2 |
| Diabetes Mellitus | 2 |
Showing 5 of 36 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 6 |
| 2021 | 2 |
| 2020 | 5 |
| 2019 | 4 |
| 2018 | 2 |
| 2017 | 2 |
Showing 10 of 16 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Biological samples | Pain | Not reported | 1 |
| Biological samples | Chronic Pain | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 3 hit target (n=3) | 0 of 1 on time (n=1) |
Journals published in (42)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMJ open | 4 |
| European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology | 3 |
| Lancet (London, England) | 3 |
| The Journal of antimicrobial chemotherapy | 3 |
| Antimicrobial resistance and infection control | 2 |
Showing 5 of 42 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 85 | 24 | 2025-11-11 |
Organization relationships (6)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Central Hospital, Nancy, France | Co sponsors trial with | 6 |
| Study Director: Anne Claire Bursztejn, PHD-MD, CHU Nancy - University of Lorraine | Co sponsors trial with | 1 |
| Institut National de la Santé Et de la Recherche Médicale, France | Co sponsors trial with | 1 |
| ONPA - Office Nancéien des Personnes Agées | Co sponsors trial with | 1 |
| Study Chair: Christophe Goetz, MD, CHR Metz-Thionville - University of Lorraine | Co sponsors trial with | 1 |
Showing 5 of 6 relationships.
Latest dated events (127)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-06-24 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-05-27 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 127 events.
Biomarker capability evidence (51)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CCL2 | Trial collaborator | Biospecimen collected in a trial |
| CRP | Trial collaborator | Biospecimen collected in a trial |
| CXCL8 | Trial collaborator | Biospecimen collected in a trial |
| EGF | Trial collaborator | Biospecimen collected in a trial |
| F3 | Trial collaborator | Biospecimen collected in a trial |
Showing 5 of 51 evidence rows.
Biomarkers this organization publishes on (551)
Shown in this order: most publications first.
Showing 5 of 551 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.